MPTP HCl induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats

MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.

MRK003 is a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

MRK-560 is a potent, brain-penetrant and orally bioavailable γ-secretase inhibitor that inhibits proteolytic cleavage of APP over the Notch pathway.

MRK-623 is a potent, α2/α3 subunit functionally selectiviie GABAA receptor agonist..

MRK-696 is a non-selective benzodiazepine receptor partial agonist..

MRK-A is a potent, highly selective, brain penetrant inhibitor of mutant IDH1 with IC50 of 5 nM, displays a 10,000-fold mutant to wildtype selectivity ratio.

MRL-1237 is a potent and selective inhibitor of the replication of Enteroviruses with EC50 of 1-10 uM, targets the nonstructural 2C protein.

MRL20 is a novel synthetic PPARγ ligand and orthosteric agonist with canonical LBP binding affinity of 2 nM.

MRL-871 (MRL871) is a potent, selective inhibitor of RORγt via allosteric inverse agonism, inhibits coactivator binding with IC50 of 7 nM; significantly reduces the IL17a mRNA levels in EL4 murine lymphoblast cell line at 10 uM.

MRS 1845 is a potent calcium channel protein inhibitor and inhibits capacitative Ca2+ influx in HL-60 cells (IC50 = 1.7 mM).

MRS 2179 is a potent, selective, competitive P2Y1 receptor antagonist with Kb of 100 nM.

MRS 2179 is a potent, selective, competitive P2Y1 receptor antagonist with Kb of 100 nM.

MRS 2481 is a potent, reversible Aβ42 neurotoxicity inhibitor with ID50 of 500 nM, potently blocks the Aβ calcium channel and protects neurons from Aβ toxicity.

MRS 2485 is a potent, irreversible Aβ42 neurotoxicity inhibitor with ID50 of 500 nM, potently blocks the Aβ calcium channel and protects neurons from Aβ toxicity..

MRS1177 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 0.3 nM.

MRS1186 is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist, with a Ki of 7.66 nM.

MRS-1706 is a potent and selective adenosine A2B receptor antagonist with Ki of 1.39 nM.

MRS1754 is a selective adenosine A2B receptor antagonist (Ki values are 1.97, 16.8, 403, 503, 570 and 612 nM for hA2B, rA1, hA1, hA2A, hA3 and rA2A receptors respectively).

MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.

MRS4458 is a potent, highly specific amtagonist of P2Y14 receptor with IC50 of 169 nM, does not display extensive off-target interactions with biogenic amine receptors..

MRS4478 is a potent, highly specific amtagonist of P2Y14 receptor with IC50 of 269 nM, does not display extensive off-target interactions with biogenic amine receptors..

MRT 199665 is a potent salt-inducible kinases (SIKs) inhibitor with IC50 of 110, 12, 43 nM for SIK1,2,3 respectively.

MRT67307 is a potent and dual IKKϵ and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively.

MRT-83 hydrochloride is a potent Smoothened antagonist that blocks Hedgehog (Hh) signaling in various assays with IC50 of 10 nM.

MRT-83 is a potent antagonist of Smo, with an IC50 in the nanomolar range.

MRTX1257 (MRTX-1257, MRTX 1257) is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 0.9 nM.

MS012 is a potent and selective inhibitor of G9a-Like Protein (GLP) lysine methyltransferase with IC50 of 7 nM, shows >30-fold selectivity for GLP over G9a and other methyltransferases..

MS-0124 is a potent and selective inhibitor of G9a-like Protein (GLP) lysine methyltransferase with IC50 of 13 nM, shows >30-fold selectivity for GLP over G9a and other methyltransferases..

MS023 is a potent, selective, and cell-active inhibitor of human type I PRMTs with IC50 of 4-119 nM.

MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 that is active in cells.

MS2734 is a bisubstrate Nicotinamide N-methyltransferase (NNMT) with IC50 of 14 uM, Kd of 2.7 uM..

MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 µM).

MS-377 is a potent, selective sigma-1 receptor ligand with Kd of 15.2 nM, showed anti-phencyclidine (PCP), anti-dopaminergic and anti-serotonergic activities.

MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice.

MS4077 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=3 nM).

MS4078 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=11 nM).

MS417 is a novel BrD inhibitor with high affinity and specificity For the BrDs of BET proteins. pIC50 7.52 (IC50 30 nM).

MS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.

MS645 (MS-645) is a novel, bivalent bromodomain (BRD) inhibitor with Ki of 18.4 nM for tandem BD1-BD2 (BRD4 BD1/BD2 ), shows12- to 28-fold gain in affinity for binding to the tandem BD1-BD2 over the single BD1 or BD2.

MS7972 is a small molecules that blocks p53 and CREB binding protein (CBP) association.

MsbA inhibitor 1 is a novel small molecule lipopolysaccharide biogenesis inhibitor, inhibits MsbA, an ATP-dependent flippase that translocates LPS across the inner membrane; causes mislocalization of LPS to the cell interior, inhibits Δ5 strain with MIC o

MSC1094308 (MSC 1094308) is a reversible, allosteric inhibitor of the type II AAA ATPase human ubiquitin-directed unfoldase (VCP)/p97 and the type I AAA ATPase VPS4B with IC50 of 7.2 and 0.71 uM, respectively.

MSC2504877 (MSC-2504877) a novel small molecule selective tankyrase inhibitor with IC50 of 0.7/0.8 nM against TNKS1/2, shows 771-fold selectivity for TNKS1 over PARP1 (IC50=0.54 uM).

MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.

MSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes.

MSN-125 (MSN 125, MSN125) is a small molecule Bax inhibitor that inhibits Bax/Bak oligomerization and prevents mitochondrial outer membrane permeabilization (MOMP) with IC50 of 4 uM.

MST312 is a telomerase inhibitor (IC50 = 0.67 μM in a TRAP assay).

MSX-122 is a n orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities.

MSX-130 is CXCR4 Antagonist.

MT1 is a bivalent chemical probe of BET bromodomains.MT1 is an intramolecular bivalent BRD4 binder that is more than 100-fold more potent, in cellular assays, than the corresponding monovalent antagonist, JQ1.

MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM).

MtbHU-IN-1 is an inhibitor of Mycobacterium tuberculosis nucleoid-associated protein HU (MtbHU), with a Kd of 98 nM for binding to WT MtbHU.

MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a Ki of 90 pM.

MTEP Hcl is a potent, selective and non-competitive mGlu5 antagonist with IC50 and Ki of 5 nM and 16 nM, respectively.

MTI31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR), displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G.

mTOR inhibitor-1 is a novel mTOR pathway inhibitor which can suppress cells proliferation and inducing autophagy.

Mtphagy Dye is a small-molecule fluorescent probe for visualizing mitophagy.

MTS is water-soluble and used in the MTS assay.

MTX-211 is a dual inhibitor of EGFR and PI3K, used for the treatment of cancer and other diseases.

MU1210 (MU-1210) is a potent and highly selective inhibitor of cdc-like kinases (CLKs) with IC50 of 51 nM (cellular BRET for CLK1).

MU1300 (MU-1300) is novel effective, selective modulator of the Hedgehog (Hh) pathway, suppresses Hh-dependent osteogenesis with IC50 of 300 nM in osteoblast differentiation assay using C3H10T1/2 cells, targets and binds to Smoothened (Smo) directly.

Mubritinib is a potent inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase.

Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC50 value being 1.8 ±1.5 μM.

Murepavadin is a novel class of highly specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas infections.

MUT-A is a novel potent, HIV-1 Integrase IN-LEDGF allosteric inhibitor, shows potent anti-HIV activity with EC50 of 32 nM and 12 nM for NL4-3 or HxB2 HIV-1 strains, respectively.

mutant EGFR inhibitor B30 is a potent, selective, next-generation EGFR mutants inhibitor with IC50 of 1.1 and 7.2 nM for EGFRL858R and EGFRL858R/T790M/C797S, respectively.

mutant IDH1 inhibitor VVS is a potent, selective mutant IDH1 inhibitor with nanomolar potency against both IDH1 R132H and IDH1 R132C, efficiently suppresses the cell-based production of D-2-HG in an HEK293 mutant embryonic kidney cell line..

Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).

MW150 (MW01-18-150SRM) is a selective, brain penetrant p38αMAPK, which is efficacious in diverse animal models of neurologic disorders.

MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM

MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM

MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.

MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.

MW181 (MW01-10-181SRM) is an isoform-selective, brain-permeable, and orally bioavailable small molecule inhibitor of p38α MAPK with Ki of 184 nM, no affitnity for CK1δ.

MX1013 is a dipeptide pan-caspase inhibitor that inhibits caspase-1

MX106 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 2.2 uM.

MX107 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 3.1 uM.

MX69 is the MDM2/XIAP inhibitor, used for cancer treatment.

MY10 is a small-molecule inhibitor of RPTPβ/ζ (PTPRZ1) with IC50 of 0.1 uM, significantly increases the phosphorylation of key tyrosine residues of RPTPβ/ζ substrates involved in neuronal survival and differentiation.

MY33-3 is a small-molecule inhibitor of RPTPβ/ζ (PTPRZ1) with IC50 of 0.1 uM, significantly increases the phosphorylation of key tyrosine residues of RPTPβ/ζ substrates involved in neuronal survival and differentiation.

MYCMI-6 (NSC354961) is a selective, high affinity inhibitor of MYC-MAX interaction, blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with Kd of 1.6 uM in SPR assay.

Mycophenolate mofetil is a prodrug for mycophenolic acid, a potent inhibitor of inosine monophosphate dehydrogenase (IC50 = 11 nM). Inhibition of this enzyme blocks de novo GTP generation as well as RNA and DNA synthesis in lymphocytes. In this way, mycop

Mycophenolic (Mycophenolate)

Mycro 3 is potent and selective for c-Myc in whole cell assays.

Myokinasib is a mixed-type, selective inhibitor of Myosin Light Chain Kinase 1 (MLCK1) with IC50 of 7.9 uM, can bind to the free enzyme and the enzyme-substrate complex.

myomiRs-IN-1 is a small-molecule probe that selectively inhibits myogenic microRNAs (myomiRs) including miR-1, miR-133a, and miR-206.

MZ1 is a PROTAC that tethers JQ1 to a ligand for the E3 ubiquitin ligase VHL, triggers, induces degradation of the BET bromodomain BRD4.

MZH29 is a novel potent, selective, orally active type II FLT3 inhibitor with IC50 of 9 nM and 7 nM against FLT3-WT and FLT3-ITD, respectively.

N-(2,2,2-trifluorethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide methanesulfonate

N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group.

N.41 (HIV inhibitor N.41, Vif inhibitor N.41) is a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G (A3G) protein (IC50=2.2 uM).

N-[2-(methylsulfanyl) phenyl]acetamide.

N1-hexyl-N5-benzyl-biguanide mesylate (HBB) is a potent and specific inhibitor of CYP3A4 AA epoxygenase activity with IC50 of 9.5 uM for inhibition of CYP3A4-mediated (±)-14,15-EET synthesis.

N2-Methylguanine is a modified nucleoside. N2-Methylguanine is an endogenous methylated nucleoside found in human fluids.

N3-PEG3-vc-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB.

N3PT(N3-pyridyl thiamine) is a potent and selective transketolase(TK) inhibitor (IC50= 22 nM for Apo-TK) both in vitro and in vivo.

N6-(2-Phenylethyl)adenosine is a selective A1 adenosine receptor agonist.

N6022 is a potent, selective, reversible, and efficacious S-Nitrosoglutathione reductase(GSNOR) inhibitor(IC50=10 nM) which is currently undergoing clinical development.

NAB-14 is a potent, selective negative allosteric modulator of GluN2C/2D-containing NMDA receptors with IC50 of 580 nM, >800-fold selective over GluN2A/GluN2 receptors; inhibits triheteromeric (GluN1/GluN2A/GluN2C) NMDARs with modestly reduced potency and efficacy compared to diheteromeric (GluN1/GluN2C/GluN2C) receptors; inhibits GluN2D-mediated synaptic currents in rat subthalamic neurons and mouse hippocampal interneurons, but has no effect on synaptic transmission in hippocampal pyramidal neurons.

Nabumetone(BRL14777) is a non-steroidal anti-inflammatory drug and its active metabolite inhibits the COX.

N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation.

N-Acetyl-Calicheamicin is a enediyne antitumor antibiotic.

NAcM-COV is a specific, irreversible small molecule inhibitor targeting N-Acetyl-UBE2M interaction with DCN1 with IC50 of 28 nM in TR-FRET assays.

NAcM-OPT is an orally bioavailable cullin neddylation 1 (DCN1) inhibitor, which potently inhibits the DCN1-UBE2M interaction.

Nacubactam (OP 0595, RG 6080, RO 7079901) is a diazabicyclooctane that inhibits class A and C β-lactamases with IC50 of <1 uM, also acts as a PBP2-active antibacterial.

Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant,showed highly potent activity against COVID-19(SARS-COV-2).

Naftopidil is an α-1-Adrenergic receptor antagonist and an antihypertensive.

Nalfurafine (TRK-820, TRK820) is potent, selective agonist of kappa-opioid receptor with Ki of 3.5 nM, 15-fold less potent for μOR and little affinity for δOR (Ki=53 and 1,200 nM, respectively).

Nalfurafine (TRK-820, TRK820) is potent, selective agonist of kappa-opioid receptor with Ki of 3.5 nM, 15-fold less potent for μOR and little affinity for δOR (Ki=53 and 1,200 nM, respectively).

Nalidixic acid (NegGram)

Naloxegol is a CYP3A4 enzyme inhibitor, is a peripherally-selective opioid antagonist, for the treatment of opioid-induced constipation.

Naloxegol is the first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.

Naloxone HCl Dihydrate is an opioid inverse agonist drug used to counter the effects of opiate overdose.

NAMI-A is a ruthenium anticancer agent and a metastasis inhibitor.

NAMPT inhibitor-linker 1 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressin

NAMPT inhibitor-linker 2 is a drug-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressin

NAN-190 is a 5-HT1A receptor antagonist with Ki of 0.6 nM.

Nanchangmycin (dianemycin) is a polyether antibiotic with similar structure to dianemycin and is very active against a broad spectrum of harmful nematodes and insects but not for for mammals and plants.

Nandrolone Decanoate is a mild form of an anabolic steroid.

Nandrolone is a synthetic, anabolic steroid analog of testosterone.

Napabucasin (BBI608) is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells.

Naphyrone (O-2482)

Naproxen is a COX inhibitor for COX-1 and COX-2 with IC50 of 8.7 μM and 5.2 μM, respectively.

Naproxen is a COX inhibitor for COX-1 and COX-2 with IC50 of 8.7 μM and 5.2 μM, respectively.

Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR (IC50=8-33 nM for (L858R, exon 19 deletion, L858R/T790M, and del19/T790M)).

Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR (IC50=8-33 nM for (L858R, exon 19 deletion, L858R/T790M, and del19/T790M)).

Naratriptan Hydrochloride is a triptan drug which is used for the treatment of migraine headaches.

Naronapride (ATI-7505) is a potent, selective and orally active 5-HT4 receptor agonist with Ki of 1.4 nM.

N-aryl benzimidazole (NAB) is a small molecule that strongly and selectively protects diverse cell types from α-syn toxicity, promotes endosomal transport events dependent on the E3 ubiquitin ligase Rsp5/Nedd4 in wild-type yeast cells..

Naspm is a selective antagonist of Ca2+-permeable AMPA receptors, blocks GluR2-lacking AMPARs, suppresses current responses induced by kainate in type II neurons with IC50 of 0.33 uM.

Naspm(1-Naphthylacetyl spermine) is a potent and selective Ca2+ permeable AMPA receptor(Ca-perm AMPAR) blocker. IC50 value: Target: CP-AMPAR blocker Naspm is a selective blocker of Ca(2+)-permeable GluA2-lacking AMPA receptors, reduced MNNG-induced CA1

Natamycin(Pimaricin)

Nateglinide is an insulin secretagog agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases.

Natural product derived from fungal source.

Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration.

NAV 2729 (NAV2729) is a chemical potentiator for mRNA-LNPs, increasing the delivery efficiencies of mRNA-LNPs in vitro and in vivo. NAV 2729 (NAV2729) is a novel, direct and selective small molecule inhibitor of small GTPase ARF6 with IC50 of 1.5 uM in nucleotide exchange assays.

Naxillin is the first non-auxin-like molecule that promotes root branching, activates a subset of auxin-induced transcripts, including AUX/IAA, SAUR and PIN families; induces auxin response in the basal meristem; represents a valuable tool to further decipher the molecular networks involved in lateral root branching.

Nazartinib(EGF816) is a novel covalent inhibitor of mutant-selective EGFR; overcomes T790M-mediated resistance in NSCLC.

NBC19 is a potent inhibitor of NLRP3 inflammasome, inhibits nigericin-induced ASC speck formation in post-differentiated THP1 cells with IC50 of 60 nM..

NBD-556 is small molecule mimetic of CD4, NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

NBD-557 is a potentially HIV-1 inhibitor.

NBI-42902 is a potent inhibitor of peptide radioligand binding to the human GnRH receptor (K(i) = 0.56 nm).

NBQX disodium is the water soluble disodium salt of NBQX, which is a potent, selective and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.15 uM.

NBQX is a potent aminomethylphosphonic acid receptor (AMPAR) antagonist with an IC50 of 0.7 ± 0.1 μM.

NC-001 (NC 001, NC001, az-NC-001) is a potent, specific, cell-permeable inhibitor of immunoproteasome caspase-like sites (β1i and β1), does not correlate with inhibition of chymotrypsin-like sites..

NC-043 (15-Oxospiramilactone) is a diterpenoid derivative inhibitor of Wnt/β-catenin signaling that interferes with the β-catenin/TCF4 association.

NCB-0846 is a novel,first-in-class,orally TNIK inhibitor with an IC50 value of 21 nM,that have shown strong anti-tumor efficacy against several cancer models.

NCC007 is a novel CKIα and CKIδ dual inhibitor. NCC007 that showed stronger period effects (0.32 μM for 5 h period lengthening) in a cellbased circadian assay.

NCD-25 is a novel potent, selective LSD1 inhibitor with IC50 of 0.48 uM, exerts highly selective inhibitory activity on LSD1 but no other enzymes, such as MAO..

NCD-38 is a novel potent, selective LSD1 inhibitor with IC50 of 0.59 uM, exerts highly selective inhibitory activity on LSD1 but no other enzymes, such as MAO (IC50>100 uM).

NCGC 00067819 is a small molecule compound that potentiates CREB signaling with EC50 of 16 nM in the primary screen and 79 nM in the CHO CRE-β-lactamase confirmation assay.

NCGC00071837 (PDE4-IN-5A) is a potent, selective PDE4 inhibitor with IC50 of 24 and 18 nM for PDE4A and PDE4D, respectively, weak inhibition for PDE4B (IC50=0.54 uM) and inactive for PDE1/3/5/7/9/10/11.

NCGC00185684 (ML154) is a potent, selective, brain penetrant NPSR (Neuropeptide S receptor.

NCGC00244536 is a potent KDM4A inhibitor with an IC50 of 10 nM.

NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.

NCT-502 is a small molecule 3-phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3.7 uM) that reduces the production of glucose-derived serine in cells and suppress the growth of PHGDH-dependent cancer cells.

NCT-503 is an inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), inhibiting serine synthesis from 3-phosphoglycerate in cells with an IC50 value of 2.5 µM.

NCT-505 is a potent and selective aldehyde dehydrogenase (ALDH1A1) inhibitor, with an IC50 of 7 nM, and weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC50s, >57, 22.8, 20.1, >57 μM).

NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with an IC50 of 7 nM.

NCX-4016 (Nitroaspirin.

ND-630 is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.

ND-646(ND646) is a small-molecule allosteric inhibitor of acetyl-CoA carboxylase (ACC).

ND-654 (ND654) is a novel potent, liver-specific acetyl-CoA carboxylase (ACC) inhibitor with IC50 of 3/8 nM for human ACC1/ACC2, respectively.

N-deacetylated BMS-202 is the deacetylated of BMS-202. BMS-202 is an inhibitor of the PD-l/PD-Ll interaction, mainly used for cancer treatment.

N-desmethyl Enzalutamide(N-desmethyl MDV3100) is a major metabolite of Enzalutamide, Enzalutamide(MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

N-Desmethylclozapine is a dengue virus inhibitor, and an agonist of δ-opioid receptor.

NDT 9513727 is a potent, selective and orally bioavailable C5a receptor inverse agonist with IC50 of 11.6 nM in radioligand binding assay.

NE 10790, a poor farnesyl pyrophosphate synthase inhibitor, is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent.

NE100 hydrochloride is a potent and selective σ1 receptor antagonist (Ki = 0.86 nM) that displays > 55-fold selectivity over σ2 receptors and > 6000-fold selectivity over D1,

Nebicapone (BIA 3-202, BIA3-202) is a potent, long-acting, reversible and competitive peripheral inhibitor of catechol-O-methyltransferase (COMT) with IC50 of 3.7 nM for rat brain COMT, much less potent for liver COMT with IC50 of 696 nM.

Nebivolol hydrochloride is a highly selective β1-adrenoceptor antagonist

Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.

Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

Necrosulfonamide (NSA) is a very specific and potent necrosis inhibitor with an IC50 less than 0.2 uM.

NecroX-5 is a novel necroptosis inhibitor that reduces mitochondrial oxidative stress, prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter.

NecroX-2 is a small molecule necrosis modulator and potent antioxidant molecule, which can be bound to some types of radicals and especially NAPQI.

Nedaplatin (Aqupla) is a derivative of cisplatin for inhibition of tumor colony forming units with IC50 of 28.5 μg/mL.

NEDD8 inhibitor M22 is a novel, potent, selective reversible NEDD8 activating enzyme (NAE) inhibitor.

Nedocromil is an inhaled anti-inflammatory agent for the preventive management of asthma.

Nefazodone hydrochloride is an antidepressant drug.

Nef-IN-B9 (Nef inhibitor B9) is a small molecule that blocks Nef-dependent Hck activity with IC50 of 2.8 uM, while the activity against Hck alone is >20 uM.

Nefiracetam is a nootropic of the racetam family. Nefiracetam is cognitive enhancer with an IC50 of approximately 150–200 μM for Ro 5-4864. This compound activates L/N-type calcium channels, cholinergic, monoaminergic and GABAergic systems. Nefiracetam di

Nefopanhydrochloride

Negative control for the Src kinase inhibitor PP2.

Negative control of (R)-PFI 2 hydrochloride. Exhibits 500-fold lower activity in a SETD7 enzymatic assay (IC50 = 1 μM) compared to the active enantiomer.

Negative control of SGC 707. Exhibits >3000-fold lower potency (IC50 >100 μM) compared to the active analog.

NEK6 inhibitor 8(ZINC05007751) is a novel inhibitor of the NIMA-related kinase NEK6 with IC50 of 3.4 uM, compound 8 is very selective against NEK1 and NEK6, while no signifcant activity was observed against NEK2, NEK7, and NEK9.

Neladenoson dalanate is a potent, selective, orally acitve partial adenosine A1 receptor (A1AR) agonist (EC50=0.1 nM) for the treatment of chronic heart failure..

Neladenoson dalanate is a potent, selective, orally acitve partial adenosine A1 receptor (A1AR) agonist (EC50=0.1 nM) for the treatment of chronic heart failure..

Nelarabine (Arranon, 506U78) is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells.

Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.

Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.

Nelonicline (ABT-126) is a potent, selective α7 nicotinic receptor (nAChR) partial agonist for the treatment of cognitive impairment with schizophrenia..

Nelotanserin is a potent 5-HT2A inverse agonist, a moderately potent 5-HT2C partial inverse agonist and a weak 5-HT2B inverse agonist, with IC50s of 1.7, 79, 791 nM in IP accumulation assays, respectively.

NEO214 (NEO-214) is a novel, BBB-permeable rolipram-perillyl alcohol conjugate, shows effectivity against both TMZ-sensitive and TMZ-resistant glioma cells (T98G IC50=40 uM).

Neoandrographolide has antiradical, anti-inflammatory,and hypolipidemic effects, it protects the cardiovascular without significant liver damage. Neoandrographolide as chemosensitizer in S-Jurkat and X chromosome-linked inhibitor of apoptosis protein (XIA

Neostigmine Bromide is a cholinesterase inhibitor used in the treatment of myasthenia gravis.